摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(9ci)-6-甲基-1H-苯并咪唑-5-胺 | 177843-72-0

中文名称
(9ci)-6-甲基-1H-苯并咪唑-5-胺
中文别名
——
英文名称
5-methyl-1H-benzimidazol-6-amine
英文别名
5-methyl-1H-benzo[d]imidazol-6-amine;6-methyl-3H-benzimidazol-5-amine;6-methyl-1H-benzimidazol-5-amine
(9ci)-6-甲基-1H-苯并咪唑-5-胺化学式
CAS
177843-72-0
化学式
C8H9N3
mdl
MFCD19216375
分子量
147.18
InChiKey
XVQBQKMMHJQBSP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    458.4±25.0 °C(Predicted)
  • 密度:
    1.295±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    54.7
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 危险性防范说明:
    P264,P270,P280,P301+P312,P305+P351+P338,P330,P337+P313,P501
  • 危险性描述:
    H302,H319
  • 储存条件:
    室温

SDS

SDS:49dd663822b5db1eb176238129ead959
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (9ci)-6-甲基-1H-苯并咪唑-5-胺盐酸硫酸盐酸羟胺双氧水 、 sodium sulfate 、 sodium hydroxide 作用下, 以 为溶剂, 反应 8.0h, 生成 5-amino-6-methyl-3H-benzimidazole-4-carboxylic acid
    参考文献:
    名称:
    Bicyclic heterocyclic anthranilic diamides as ryanodine receptor modulators with insecticidal activity
    摘要:
    The diamide insecticides act on the ryanodine receptor (RyR). The synthesis of various bicyclic anthranilic derivatives is reported. Their activity against the insect ryanodine receptor (RyR) and their insecticidal activity in the greenhouse is presented, as well as structure activity relationship considerations. (C) 2015 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2015.11.035
  • 作为产物:
    描述:
    5-甲基苯并咪唑 在 palladium on activated charcoal 硫酸氢气potassium nitrate 作用下, 以 乙醇 为溶剂, 反应 17.0h, 生成 (9ci)-6-甲基-1H-苯并咪唑-5-胺
    参考文献:
    名称:
    Structure−Activity Relationship Studies of Novel Benzophenones Leading to the Discovery of a Potent, Next Generation HIV Nonnucleoside Reverse Transcriptase Inhibitor
    摘要:
    Despite the progress of the past two decades, there is still considerable need for safe, efficacious drugs that target human immunodeficiency virus (HIV). This is particularly true for the growing number of patients infected with virus resistant to currently approved HIV drugs. Our high throughput screening effort identified a benzophenone template as a potential nonnucleoside reverse transcriptase inhibitor (NNRTI). This manuscript describes our extensive exploration of the benzophenone structure-activity relationships, which culminated in the identification of several compounds with very potent inhibition of both wild type and clinically relevant NNRTI-resistant mutant strains of HIV. These potent inhibitors include 70h (GW678248), which has in vitro antiviral assay IC50 values of 0.5 nM against wild-type HIV, 1 nM against the K103N mutant associated with clinical resistance to efavirenz, and 0.7 nM against the Y181C mutant associated with clinical resistance to nevirapine. Compound 70h has also demonstrated relatively low clearance in intravenous pharmacokinetic studies in three species, and it is the active component of a drug candidate which has progressed to phase 2 clinical studies.
    DOI:
    10.1021/jm050670l
点击查看最新优质反应信息

文献信息

  • Src kinase inhibitor compounds
    申请人:Merck & Co., Inc.
    公开号:US06498165B1
    公开(公告)日:2002-12-24
    Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.
    嘧啶化合物(化学式I),或其药用可接受的盐、水合物、溶剂合物、晶型和单一对映异构体,以及包括这些化合物的药物组合物,它们是酪氨酸激酶酶的抑制剂,因此在预防和治疗蛋白酪氨酸激酶相关疾病方面具有用处,如免疫疾病、高增殖性疾病和其他认为不当的蛋白激酶作用可能起作用的疾病,如癌症、血管生成、动脉粥样硬化、移植排斥、类风湿性关节炎和牛皮癣。
  • Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents
    申请人:N30 Pharmaceuticals, Inc.
    公开号:US09138427B2
    公开(公告)日:2015-09-22
    The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
    本发明涉及S-亚硝基谷胱甘肽还原酶(GSNOR)的抑制剂,包括这种GSNOR抑制剂的药物组合物,以及制备和使用这些药物的方法。
  • [EN] NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS<br/>[FR] NOUVEAUX INHIBITEURS PYRROLE DE S-NITROSOGLUTATHIONE RÉDUCTASE EN TANT QU'AGENTS THÉRAPEUTIQUES
    申请人:N30 PHARMACEUTICALS LLC
    公开号:WO2010019903A1
    公开(公告)日:2010-02-18
    The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
    本发明涉及S-亚硝基谷胱甘肽还原酶(GSNOR)的抑制剂,包括这样的GSNOR抑制剂的制药组合物,以及制备和使用这些组合物的方法。
  • Novel benzimidazole derivatives
    申请人:Synaptic Pharmaceutical Corporation
    公开号:US20030181730A1
    公开(公告)日:2003-09-25
    This invention provides compounds having the structure: 1 wherein each of R 1 , R 2 , R 3 and R 9 is independently H; straight chain or branched, substituted or unsubstituted C 1 -C 7 alkyl, C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or cycloalkenyl; acyl, phenyl, substituted phenyl, or heteroaryl; wherein each dashed line represents a single bond or a double bond with the proviso that if R 1 is present, R 3 is absent and there is a double bond between N at position 3 and C at position 2 and a single bond between C at position 2 and N at position 1 and if R 3 is present, R 1 is absent and there is a double bond between N at position 1 and C at position 2 and a single bond between C at position 2 and N at position 3; wherein each of R 4 , R 5 and R 6 is independently H, F, Cl, Br, I; straight chain or branched, substituted or unsubstituted C 1 -C 7 alkyl, C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or cycloalkenyl; phenyl, substituted phenyl, heteroaryl, —OH, —OR 7 , —CN, —COR 7 , —CO 2 R 7 , —CON(R 7 ) 2 , —OCOR 7 , —SR 7 , —N(R 7 ) 2 , —NR 7 COR 7 , —(CH 2 ) n OR 7 , —(CH 2 ) n N(R 7 ) 2 , —(CH 2 ) n NR 7 COR 7 , wherein n is an integer from 1 to 4; and wherein each of R 7 and R 8 is independently H; straight chain or branched, substituted or unsubstituted C 1 -C 7 alkyl, C 2 -C 7 alkenyl or alkynyl; phenyl or substituted phenyl. These compounds are selective for cloned human alpha 2 receptors and are useful as analgesic, sedative or anaesthetic agents.
    本发明提供具有结构的化合物:1其中R1,R2,R3和R9中的每一个都是独立的H; 直链或支链,取代或未取代的C1-C7烷基,C2-C7烯基或炔基; C3-C7环烷基或环烯基; 酰基,苯基,取代苯基或杂环基; 其中每个虚线代表单键或双键,前提是如果R1存在,则R3不存在,并且在位置3处的N和位置2处的C之间有双键,在位置2处的C和位置1处的N之间有单键,如果R3存在,则R1不存在,并且在位置1处的N和位置2处的C之间有双键,在位置2处的C和位置3处的N之间有单键; 其中R4,R5和R6中的每一个都是独立的H,F,Cl,Br,I; 直链或支链,取代或未取代的C1-C7烷基,C2-C7烯基或炔基; C3-C7环烷基或环烯基; 苯基,取代苯基,杂环基,—OH,—OR7,—CN,—COR7,—CO2R7,—CON(R7)2,—OCOR7,—SR7,—N(R7)2,—NR7COR7,—(CH2)nOR7,—(CH2)nN(R7)2,—(CH2)nNR7COR7,其中n是1到4的整数; 其中R7和R8中的每一个都是独立的H; 直链或支链,取代或未取代的C1-C7烷基,C2-C7烯基或炔基; 苯基或取代苯基。 这些化合物对克隆的人类α2受体具有选择性,并可用作镇痛,镇静或麻醉剂。
  • Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents
    申请人:Wasley Jan
    公开号:US20110144110A1
    公开(公告)日:2011-06-16
    The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
    本发明涉及S-亚硝基谷胱甘肽还原酶(GSNOR)的抑制剂,包括这种GSNOR抑制剂的药物组合物,以及制备和使用它们的方法。
查看更多